Johnson & Johnson is reportedly on track to meet its vaccine distribution goal; FDA grants emergency use authorization to Amazon for an at-home COVID-19 test; 6 states expand vaccine eligibility to all adults, with 3 more states to follow later this week.
Reported by POLITICO, the Biden administration said last Friday that Johnson & Johnson (J&J) is on track to meet its distribution goal of 20 million doses of its COVID-19 vaccine by month’s end after reports that it could potentially miss its vaccine delivery deadline. Having sent 4 million of the 20 million doses to states and federal partners, White House coronavirus response coordinator Jeff Zients said the company is due to send the government 11 million more doses this week, with expectations of a significant increase in doses by the end of March to meet its goal.
The FDA granted emergency use authorization (EUA) to Amazon for an at-home nasal swab and PCR-based test for COVID-19, according to STAT. Called the Amazon COVID-19 Collection Kit, the test would allow users to self-test without supervision of a health care professional. The move adds to Amazon’s foray into health care, with its virtual-first health care platform, Amazon Care, announced to be made available to all its workers and to interested private employers by this summer.
Today, 6 states—Kansas, Louisiana, North Dakota, Ohio, Oklahoma, and Texas—are expanding eligibility for the COVID-19 vaccine to all adults, with Minnesota, Indiana, and South Carolina to follow later this week. As reported by The New York Times, cases of COVID-19 have risen significantly over the past week, with approximately 15,000 more cases this past Friday compared with the Friday before. Nearly all states have pledged to expand vaccine eligibility to all adults by May 1; Northeastern states accounted for about 30% of new US cases in the past 2 weeks.
Elevated Inflammatory Marker Levels Associated With Increased Overactive Bladder Risk
April 15th 2025Systemic immune inflammation index, neutrophil-to-lymphocyte ratio, and systemic inflammation response index levels may offer a noninvasive method to identify individuals at increased risk of developing overactive bladder.
Read More
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
SGLT2 Inhibitors Show Renal Benefits in HF and CKD as Prescribers Target Uptake Gaps
April 15th 2025Abstracts featured at the National Kidney Foundation Spring Clinical Meeting highlighted the renoprotective benefits of SGLT2 inhibitors in heart failure and diabetic kidney disease while emphasizing the need for strategies to increase their uptake in primary care.
Read More